Acrixolimab is under clinical development by Y-Biologics and currently in Phase II for Non-Small Cell Lung Carcinoma. According to GlobalData, Phase II drugs for Non-Small Cell Lung Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Acrixolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acrixolimab overview
Acrixolimab (YBL-006) is under development for the treatment of non-small cell lung cancer, recurrent head and neck squamous cell carcinoma, non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, hurthle cell thyroid carcinoma, kidney cancer, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer. It is administered through intravenous route. It acts by targeting programmed cell death protein 1 (PD1) and programmed cell death 1 ligand 1 (PD L1). The drug candidate is a monoclonal antibody developed based on human antibody library (Ymax-ABL), receptor library (Ymax-CEPT) and mammalian transient expression (Ymax-tEXPRESS).
It was under development for the treatment of melanoma and colorectal cancer.
Y-Biologics overview
Y-Biologics is a biopharmaceutical company that focuses on antibody therapeutics in cancer, autoimmune diseases, and metabolic disease. It is headquartered in Daejeon, South Korea.
For a complete picture of Acrixolimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
